2. Immunology/Inflammation NF-κB
  3. CD20 NF-κB
  4. Anti-Mouse CD20 Antibody (18B12)

Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8+ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury.

For research use only. We do not sell to patients.

Anti-Mouse CD20 Antibody (18B12)

Anti-Mouse CD20 Antibody (18B12) Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anti-Mouse CD20 Antibody (18B12) Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8+ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury[1][2][3].

Isotype

Mouse IgG2a kappa
Recommend Isotype Controls
Species Reactivity

Mouse
In Vitro

Anti-Mouse CD20 Antibody (18B12) (4.35 μg/μl; 1 h pre-injury pretreatment, 24 h post-injury in medium) reduces cell death and nitric oxide production in postnatal day 6 mouse spinal cord organotypic slices 24 h after mechanical damage[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse CD20 Antibody (18B12) Related Antibodies
In Vivo

Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) induces a modest, transient slowing of AB12 mesothelioma growth in BALB/c mice, with up to 60% reduction in tumor burden observed depending on treatment timing[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) slows growth of established AB12 mesothelioma in BALB/c mice, with up to 70% reduction in tumor burden observed in mice with 7-day established tumors[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 8 post-tumor inoculation) administered in combination with Ad.E7 vaccination induces marked regression of established TC1 lung cancer in C57BL/6 mice, with 67% of tumors completely regressing and cured mice resistant to rechallenge, accompanied by robust systemic and intratumoral tumor antigen-specific CD8+ T-cell responses[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) induces sustained B-cell depletion in healthy mice, with >90% depletion of blood and lymph node B cells, 84% depletion of splenic B cells by day 7, and variable depletion of splenic B-cell subpopulations[1].
Anti-Mouse CD20 Antibody (18B12) (5 mg/kg; i.v.; 3 doses on day 19, day 22, day 25 after reaching EAE score ≥2.5) potently depletes 94% of total splenic B cells and reduces CNS-infiltrating B cell infiltrates by up to 77% in wild-type C57BL/6 mice with chronic EAE, but does not improve clinical disease, serum antibody levels, or spinal cord myelination[2].
Anti-Mouse CD20 Antibody (18B12) (30 mg/kg; i.p.; two doses at 1 hour and 6 hours after injury) reduces spinal cord tissue damage, improves hindlimb motor function, inhibits NF-κB pathway activation, lowers proinflammatory mediator and cytokine expression, and reduces immune cell infiltration/activation in a mouse model of SCI[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD1 mice (male, adult, 25-30 g, laminectomy and aneurysm clip compression injury modeling)[3]
Dosage: 30 mg/kg
Administration: i.p.; two doses at 1 hour and 6 hours after injury
Result: Lowered histological score (0-9 scale) from ~7.5 in untreated mice to ~3.5 in treated mice.
Improved Basso Mouse Scale (BMS) score to ~6 at 6 weeks after injury, compared to ~3.5 in untreated mice.
Restored IkB-α levels to near sham-operated mouse levels, preventing SCI-induced IkB-α degradation.
Significantly reduced nuclear NF-kB p65 expression compared to untreated mice.
Significantly reduced spinal cord expression of inducible nitric oxide synthase (iNOS) compared to untreated mice.
Reduced spinal cord expression of proinflammatory cytokines IL-1β and IL-12A, and lowered the percentage tissue area of TNF-α immunoreactivity from ~7% in untreated mice to ~2.5% in treated mice.
Lowered percentage tissue area of GFAP immunoreactivity from ~7.5% in untreated mice to ~2.5% in treated mice, decreasing astrocyte activation.
Lowered CD19+ B lymphocyte, CD11β+ microglial/macrophage, CD8β+, CD4+, and CD45+ T lymphocyte immunoreactivity in spinal cord tissue, reducing immune cell infiltration and activation.
Lowered percentage tissue area of Foxp3+ regulatory T cell immunoreactivity from ~8% in untreated mice to ~3% in treated mice.
Gene ID

12482  [NCBI]

Accession
Target

CD20
Application

ELISA, FACS, Functional assay, Research in vivo
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

[Anti-Mouse CD20 Antibody (18B12)]
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anti-Mouse CD20 Antibody (18B12) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse CD20 Antibody (18B12)CD20NF-κBNuclear factor-κBNuclear factor-kappaBantibody-dependent cell phagocytosismouse CD20B cellsmesotheliomaantibody-dependent cell-mediated cytotoxicityexperimental autoimmune encephalomyelitissplenic B-cell subpopulationsthymomamarginal zone B cellslung cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anti-Mouse CD20 Antibody (18B12)
Cat. No.:
HY-P992060
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.